Physician profile
Mark B Sender
NPI 1013097534
$12,880.91
in general payments reported to CMS, 2019-2025
52 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $1,048 · 2021: $3,171 · 2022: $2,129 · 2023: $1,998 · 2024: $1,994 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,952 · Travel and Lodging: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,952.35 |
| Travel and Lodging | $537.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $3,125.31 | 2021-2023 | |
| Cipla USA INC. | $1,228.93 | 2020-2022 | |
| Abbvie INC. | $731.39 | 2019-2025 | Botox, Lupron Depot |
| Coloplast Corp | $701.54 | 2019-2024 | Speedicath |
| Astellas Pharma US INC | $678.74 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $453.49 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Edap Technomed INC | $447.00 | 2024 | |
| Medtronic USA, INC. | $439.14 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $433.20 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $429.45 | 2024-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $405.46 | 2021-2025 | Urolift, Barrigel |
| Antares Pharma, INC. | $356.30 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $285.52 | 2019-2025 | |
| Allergan, INC. | $267.41 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $244.41 | 2019-2024 | Xiaflex |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379,273.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.